Jeffrey R. Infante,Antoine Hollebecque,Sophie Postel-Vinay,Todd M. Bauer,Elizabeth M. Blackwood,Marie Evangelista,Sami Mahrus,Franklin V. Peale,Xuyang Lu,Srikumar Sahasranaman,Rui Zhu,Yuan Chen,Xiao Ding,Elaine R. Murray,Jennifer L. Schutzman,Jennifer O. Lauchle,Jean-Charles Soria,Patricia M. LoRusso

Abstract:Supplemental Figure 3. Clinical trial tumor immunohistochemistry. Representative images from tumor biopsies were analyzed for pCDK1/2 and Ki-67expression. Representative images from a patient with NSCLC and unknown p53 mutation status were obtained 24 hours after administration of GDC-0425 alone (A, B), 48 hours after gemcitabine alone (C, D) and at a time point that was both 24 hours after GDC-0425 and 48 hours after gemcitabine (E, F). Quantitation of percent tumor cell Ki-67 positivity varied minimally between biopsies (G); pCDK1/2 increased from baseline after gemcitabine treatment, whereas the combination of GDC-0425 given 24 hours after gemcitabine suppressed the increase in pCDK1/2. Scale bar=40 Âµm.

Supplementary Figure 7 from Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

Supplementary Figure 4 from Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

Supplementary Figure 6 from Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

Supplementary Figure 5 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

Supplementary Figures 1-3 from the Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Supplementary Figure 4 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Supplementary Figure S7 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase Is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Supplementary Figures 1-3 from Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity

Supplementary Figure S5 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Supplementary Figures 5 - 6 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Supplementary Figure 2 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Supplementary Figure S2 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase Is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Supplementary Figure 6 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth

Supplementary Figure S6 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase Is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Supplemental Figure 3 from Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Supplementary Figure 4 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure from DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy

Supplementary Figure 9 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure Legends 1- 4 from PTEN Loss Accelerates <i>Kras</i><sup><i>G12D</i></sup>-Induced Pancreatic Cancer Development